Funding
Xspray Pharma Registers Disclosure Document for SEK 90 Million Rights Issue With Over-Allotment Option
By News Desk ·
Key takeaways
- Xspray Pharma's board resolved the rights issue of approximately SEK 90 million on November 6, 2026, under an authorization from the annual general meeting held on May 12, 2026.
- The rights issue may be increased by up to approximately SEK 72 million through an over-allotment issue.
- The subscription period runs from November 17 to December 1, 2026, with the outcome expected around December 3, 2026.
Xspray Pharma AB (publ) has published a disclosure document for a rights issue of ordinary shares of approximately SEK 90 million, which its board resolved on November 6, 2026, under an authorization from the annual general meeting held on May 12, 2026. TradingView reported the filing on November 13, 2026.
How the Xspray Rights Issue Is Structured
The rights issue carries preferential rights for existing shareholders and may be increased by up to approximately SEK 72 million through an over-allotment issue. The disclosure document was prepared under Article 1.4 db and Article 1.5 ba of the Prospectus Regulation and in line with Annex IX, and it has been registered with the Swedish Financial Supervisory Authority. The document is available on Xspray Pharma's website and on Aqurat's website.
The record date for participation is November 13, 2026, the same day the disclosure document was published. Trading in subscription rights runs from November 17 to November 26, 2026, and the subscription period from November 17 to December 1, 2026. Trading in paid subscribed shares runs from November 17 to December 16, 2026.
Zonda Partners acts as sole global coordinator and sole bookrunner, and Vinge acts as legal adviser. Jacob Nyberg is named as investor relations contact.
Xspray's Path to the November Filing
On November 6, 2026, Xspray Pharma published its interim report for the third quarter of 2026, showing net sales of SEK 0 and a net loss of SEK 114.5 million for the first nine months, according to TradingView. The same day, MarketScreener reported that the FDA began an unannounced follow-up inspection of Xspray's contract manufacturer Nerpharma in Italy over cGMP deficiencies.
On October 2, 2026, MarketScreener reported that Xspray still targets resubmission of the Dasynoc and Nilopki applications in the fourth quarter of 2026. Dagens industri reported the same day that chief executive Blake Leitch said the company can reach break-even within 7 to 12 months.
Other Rights Issues in the Market
Vuno deferred its 6,300,000-share rights offering timetable after the Financial Supervisory Service requested an amended filing on November 10, 2026, The future of trading reported on November 11, 2026. Bloomberg reported on November 9, 2026, that First Abu Dhabi Bank executives held preliminary discussions on a potential rights issue to raise about $5 billion.
ScanX reported on November 9, 2026, that Ampvolts Limited's board will meet on November 16, 2026, to consider increasing authorized share capital and raising funds through instruments including rights issues.
Xspray's Expected Outcome Date
Xspray expects to announce the outcome of the rights issue around December 3, 2026. The company describes the timetable as preliminary and subject to adjustment.